Skip to main content

Allergy, Insect Venom

0
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Inmunotek
InmunotekSpain - Madrid
2 programs
VENOXN/A1 trial
VENOXN/A1 trial
Active Trials
NCT06782217Recruiting120Est. Feb 2027
NCT06790368Recruiting80Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
InmunotekVENOX
InmunotekVENOX

Clinical Trials (2)

Total enrollment: 200 patients across 2 trials

Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.

Start: Jan 2025Est. completion: Jun 202680 patients
N/ARecruiting

Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy

Start: Sep 2024Est. completion: Feb 2027120 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 200 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.